



## The Forum HIV Prevention Trial Design Public Meeting Series

Webinar 2: High-level review of regulatory frameworks and the way forward

Tuesday, November 10, 2020 11 am - 1 pm EST

Webinar

## Overview

The 2nd webinar will discuss the potential path forward regarding clinical trial designs. Similar to the 1st webinar, the 2nd webinar will continue to review the regulatory framework for clinical trial innovation relevant for PrEP. Experts from the US and South Africa will provide a high-level overview. The goal of the first two information webinars is to bring the audience up to speed and facilitate their engagement in strategic discussions on forging a feasible path forward. Both webinars will be archived for future access.

## **AGENDA**

11:00 AM	Welcome & Housekeeping	Tamar Tchelidze, MD, MPH, Sr. Policy Fellow. Forum for Collaborative Research, UC Berkeley
	Opening remarks	Veronica Miller, PhD, Executive Director, Forum for Collaborative Research, UC Berkeley
11:10 AM	Session I: High-level Overview of Regulatory Frameworks & Global In	nitiatives
11:10 AM	Moderator	Ken Mayer, MD, Medical Research Director. The Fenway Institute/Harvard Medical School
11:10 AM	Regulatory Frameworks - Africa Perspective	Boitumelo Semete-Makokotlela, PhD, MS, Chief Executive Officer of SAHPRA.
11:20 AM	WHO Pre-Qualification Program	Regine Lehnert, MD, adviser to WHO prequalification programme
11:35 AM	Session II: Identifying the need for change	
	Moderator	Veronica Miller, Forum for Collaborative Research, UC Berkeley
11:35 AM	Why do we need a new approach?	Mitchell Warren, BA, Executive Director, AVAC
11:45 AM	Why are we talking about an external control (counterfactual) approach; when has this approach been used in the past? What are the regulatory underpinnings?	Jeffrey Murray, MD, MPH. Deputy Director of the Division of Antiviral Products (DAVP), FDA
12:00 PM	What is a counterfactual and how can a counterfactual external control approach be used in HIV prevention research?	Sandra McCoy, PhD, MPH, Associate Professor, Division of Epidemiology and Biostatistics.UC Berkeley
12:15 PM	Moderated discussion with panelists	Community representatives: Lynda Dee, co-founder AIDS Action Baltimore (US), David Haerry, EATG (EU), Definate Nhamo, Pangaea Zimbabwe AIDS Trust, (Africa).
12:40 PM	Q & A	
1:00 PM	ADJOURN	